BioPharma Resources

Drug Trial Radar · NCT05686356

A Pan-TB Regimen Targeting Host and Microbe

A Novel 4-month Pan-TB Regimen Targeting Both Host and Microbe (panTB-HM)

Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

352

Planned (sponsor's estimate)

Start

Jul 28, 2023

Primary completion

Jan 2026

Study completion Jan 2026

Sponsor

Lead sponsor
The Aurum Institute NPCAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ludwig-Maximilians - University of Munich; Stichting Katholieke Universiteit; Wits Health Consortium (Pty) Ltd; Instituto Nacional de Saúde, Mozambique; National Institute for Medical Research, Tanzania; University of Stellenbosch; Sequella, Inc.; Global Alliance for TB Drug Development
First posted
Jan 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, not requiring knowledge of RIF susceptibility. The regimen will test sutezolid at 2 dose levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial. It will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed WHO essential medicine, can protect the lung and liver against oxidative damage, preserve lung function, and accelerate the eradication of MTB infection by replenishing glutathione (GSH).

Conditions

  • Tuberculosis

Interventions

  • SutezolidDrug

    Sutezolid will be given at a dose of 1200mg QD in arm 1 and at a dose of 1600mg QD in arms 2 and 3.

  • N-acetyl cysteineDrug

    NAC will be given at a dose of 1800 mg BID in arm 3

  • PretomanidDrug

    Pretomanid will be given at its approved dose

  • BedaquilineDrug

    Bedaquiline will be given at its approved dose

  • RifafourCombination product

    Fixed dose combination tablets for TB treatment will be given at approved doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients achieving durable (non-relapsing) cureTime frame: Assessed after 1 year of post-treatment follow-up

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • Instituto Nacional de Saúde

    Maputo, Mozambique

  • Clinical HIV Research Unit

    Durban, Durban, South Africa

  • Clinical HIV Research Unit

    Johannesburg, Gauteng, South Africa

  • The Aurum Institute: Tembisa Clinical Research Centre

    Tembisa, Gauteng, South Africa

  • The Aurum Institute, Gavin J Churchyard Legacy Centre (Klerksdorp Clinical Research Centre)

    Klerksdorp, Klerksdorp, South Africa

  • The Aurum Institute, Rustenburg Clinical Research Centre

    Rustenburg, North West Provice, South Africa

  • TASK Eden

    George, Western Cape, South Africa

  • NIMR-Mbeya Medical Research Centre

    Mbeya, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.